Close Menu

equity investment

Clinical informatics startup Ovation looks to grow its business in laboratory information systems for precision molecular diagnostic labs.

Freshly minted as a "unicorn," the Utah healthcare data analytics powerhouse is building up a new life sciences division to aid biotech development and precision medicine.

Emedgene, which makes AI-based, automated genomic interpretation software, will use the Series A funding to expand its US sales operations.

The genome informatics company will apply the new capital to deploy the DNAnexus Apollo platform for multi-omics data science exploration, analysis, and discovery.

The firm said it raised €55.5 million to fund the expansion of its Idylla test platform, its sales and marketing activities, and other general corporate purposes.

The Belgium-based firm plans to use the proceeds to fund expansion of the Idylla test platform, sales and marketing activities, and additional general corporate purposes.

The Series E financing will go, in part, toward expansion of the company's US presence by growing its workforce and marketing to more American hospitals.

Foresite Capital and F-Prime Capital joined previous investors in this second Series B closing, bringing the total Series B value to £33 million.

Privately owned Oxford Nanopore offers a range of tools and and instruments based on a proprietary nanopore-based DNA and RNA sequencing technology.

Vertex Pharmaceuticals has invested £10.5 million in the British analytics company as the companies launch a multiyear R&D partnership seeking novel drug targets.

Pages

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.